Skip to main content

DNA Nanorobot Delivers Antisense Oligonucleotides Silencing c-Met Gene Expression for Cancer Therapy

Buy Article:

$107.14 + tax (Refund Policy)

Antisense oligonucleotides are considered to be a promising strategy for cancer therapy because of their high specificity and minimal side effects. They can bind specifically to mRNA silencing the expression of target genes. However, ssDNA cannot enter cells in large quantities, which limits its applications. Tetrahedral framework nucleic acids (tFNA) are considered to be optimal nanoscopic drug carriers because of their editability and biocompatibility. Most importantly, they can be modified with functional molecules. The over-expression of c-Met is associated with a wide variety of tumor occurrences, developments, drug resistance and prognoses. Activation of HGF/c-Met signaling pathways can promote cell migration and invasion in cancer. Therefore, blocking the expression of c-Met is a valid technique for cancer therapy. In this study, we used tFNA as carriers to deliver antisense oligonucleotides, which can bind to c-Met mRNA with high specificity and affinity, into cells resulting in the inhibition of c-Met expression for cancer therapy.

Keywords: ANTISENSE OLIGONUCLEOTIDES; CANCER THERAPY; CELL MIGRATION; HGF/c-MET SIGNALING PATHWAY; tFNA

Document Type: Research Article

Publication date: 01 September 2019

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content